0001140361-19-004456.txt : 20190305
0001140361-19-004456.hdr.sgml : 20190305
20190305192332
ACCESSION NUMBER: 0001140361-19-004456
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190301
FILED AS OF DATE: 20190305
DATE AS OF CHANGE: 20190305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shah Gaurav
CENTRAL INDEX KEY: 0001725922
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36829
FILM NUMBER: 19660667
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
STREET 2: SUITE 1040
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ROCKET PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001281895
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
BUSINESS PHONE: 646-440-9100
MAIL ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
FORMER COMPANY:
FORMER CONFORMED NAME: INOTEK PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20040226
4
1
form4.xml
FORM 4
X0306
4
2019-03-01
0001281895
ROCKET PHARMACEUTICALS, INC.
RCKT
0001725922
Shah Gaurav
C/O ROCKET PHARMACEUTICALS, INC.
350 FIFTH AVENUE, SUITE 7530
NEW YORK
NY
10118
true
true
See Remarks
Common Stock
2019-03-01
4
S
0
25000
17.34
D
736850
D
Common Stock
2019-03-04
4
S
0
24900
17.28
D
711950
D
Common Stock
2019-03-05
4
S
0
25000
16.9
D
686950
D
This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.01 to $17.56. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $16.76 to $17.71. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $16.43 to $17.73. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
President and Chief Executive Officer
/s/ Sara Turken, as attorney-in-fact for Gaurav Shah
2019-03-05